Patiromer in Patients with Kidney Disease and Hyperkalemia Receiving RAAS Inhibitors
Matthew R. Weir(University of Maryland, Baltimore), Bertram Pitt(Bayer (Germany)), Janet Wittes(Deloitte (United States)), Yuri Stasiv, Dahlia Garza, Heidi Christ‐Schmidt(Statistics Collaborative), David A. Bushinsky(University of Rochester), Lance Berman, Martha Mayo, George L. Bakris(Pennsylvania State System of Higher Education)
Cited by 658
Related Papers
Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
|Hypertension|2003|13.3k
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
|New England Journal of Medicine|1999|9.1k
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
|New England Journal of Medicine|2019|6k
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
|Survey of Anesthesiology|2000|2.9k
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2020|2.6k